Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 4/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 4/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30458541 | 0.83 | PLK4 (0.35) | PLK4TBK1HTR2ADAPK1CDK4 | |
| SCHEMBL13071529 | 0.81 | HTR2A (0.39) | PLK4TDP1MAPTTSHRMAPK1 | |
| SCHEMBL1537641 | 0.81 | TSHR (0.37) | TDP1MAPTTSHRMAPK1CASP1 | |
| SCHEMBL12913620 | 0.79 | CASR (0.43) | TDP1MAPTTSHRMAPK1CASP1 | |
| SCHEMBL30039598 | 0.79 | POLB (0.38) | TDP1MAPTTSHRMAPK1CASP1 | |
| SCHEMBL13543521 | 0.77 | CYP1A2 (0.49) | MAPTTSHRATMCYP11B2ALDH1A1 | |
| SCHEMBL20311307 | 0.76 | PLK4 (0.41) | PLK4TBK1CDK4CDK1CCNB1 | |
| SCHEMBL5146857 | 0.75 | CYP11B2 (0.40) | MAPTMAPK1HTR2AHTR2CCYP11B2 | |
| SCHEMBL5144181 | 0.75 | DAO (0.39) | MAPTMAPK1HTR2AHTR2CCYP11B2 | |
| SCHEMBL28657156 | 0.75 | PLK4 (0.34) | PLK4TBK1TDP1CDK4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626423-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| CN-119707834-A | Preparation method of arbeli and intermediate thereof | 常州制药厂有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2025-02-27 | — | — | US | disclosed |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | SHANGHAITECH UNIVERSITY (CN) | 2025-02-18 | — | — | US | disclosed |
| CN-118510516-A | Pharmaceutical combination comprising arbelii and PI3K and/or MTOR inhibitors for the treatment of mantle cell lymphoma | 德克萨斯州大学系统董事会 | 2024-08-16 | — | — | CN | disclosed |
| US-20240252688-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. | 2024-08-01 | — | — | US | disclosed |
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2022-04-21 | — | — | US | disclosed |
| CN-110218189-A | A kind of simple and convenient process for preparing of Abbe Seeley intermediate and Abbe Seeley | 新发药业有限公司 | 2019-09-10 | — | — | CN | disclosed |
| CN-106928219-A | Nitrogenous fused heterocyclic compound, preparation method, intermediate, composition and application | 上海医药集团股份有限公司 | 2017-07-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | PLK4 1977/4885TBK1 567/4885TDP1 3871/4885 |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | UFM1, SUMO1, SUMO2 | PLK4 1701/4885TBK1 653/4885TDP1 3964/4885 |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | PLK4 1701/4885TBK1 653/4885TDP1 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.